A rapid blood protein test can detect a brain injury in minutes

A rapid blood protein test can detect a brain injury in minutes

Washington: In a breakthrough study, researchers found that a blood protein test can detect the severity of head trauma in less than 15 minutes.
The new research was recently published in the Journal of Neurotroma.
Demonstrating that glycyrrhizic acid protein (GFAP) can accurately determine the severity of brain injury through blood tests, the research team working on this study, author David Okunko, MD, Ph.D. A point of care developed by the Professor of Neurological Surgery at the Neprotoma Clinical Trials Center of UPMC and the University of Pittsburgh School of Medicine, led by the Director of Advanced testing device development.
For rapid detection, the vision involves the use of a hand-held device, including a cartilage traumatic brain injury that will measure GFAP in a patient’s blood. Researchers at Abbott Laboratories, a global healthcare company, will need to finalize tests for the I-STAT device, which is already being used by military and healthcare providers around the world to make numerous blood tests common. Used for A blood test can show a patient’s GFAP level.
“This will eliminate the risk of a TBI diagnosis and will determine if an individual needs further treatment,” O’Connor said.
Okakuno added, “Whether you are examining a wounded soldier or a patient in a small rural hospital with minimal resources, the health care provider needs the necessary information – in minutes – They may be needed to treat every patient’s brain injury. ” .
For this study, which expanded the results of previous GFAP, researchers enrolled 1,497 individuals who completed one of 18 transforming research and clinical knowledge at TBI (TRACK-TBI) Level 1 trauma centers over a four-year period. But sought care.
GFAP is a Food and Drug Administration-approved marker to rule out whether a patient needs a head computed tomography (CT) scan within 12 hours after a mild TBI.
For years, scientists have studied blood tests involving GFAP. They have also studied a similar protein called S100B. Both proteins are released into the bloodstream in response to specific injuries, including TBI. But this study shows that GFAP performed significantly better than the S100B as a TBI diagnostic marker.
“Knowing this protein can reveal the severity of TBI through simple blood tests when it is thought that we could use a device that is already widely used in hospitals, doctors’ offices and emergency care facilities. All we have to do is add an extra cartridge to the device to analyze the blood for GFAP protein, Okonkwo said.
He estimated that the device could reduce potentially unnecessary CT scans by 20% or more, at a cost of 100 100 million annually.

STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ

Leave a Reply

Your email address will not be published. Required fields are marked *